TORONTO, Feb. 23 /CNW/ - Transition Therapeutics Inc. (“Transition”) (TSX: TTH) announced that a presentation of positive preclinical data with Alzheimer’s disease lead product AZD-103 was made at the Keystone Symposia on Alzheimer’s Disease held in Breckenridge, Colorado. A series of preclinical studies in a widely accepted animal model of Alzheimer’s disease showed that AZD-103 can prevent and reduce disease effects including the formation of amyloid beta fibrils, impaired cognitive function and accelerated mortality. These outcomes occurred regardless of whether AZD-103 was administered before the onset of disease or during the symptomatic phase of disease indicating AZD-103’s potential as a preventative and therapeutic agent for Alzheimer’s disease.
